Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | LAP3 | P28838 | 2/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.61 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ubenimex SCHEMBL8191715 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5057802 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5819609 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL16782425 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5812930 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL9247599 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5807154 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL16782424 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL22632072 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL7943 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 39755 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| CN-122057033-A | Method for modifying drug molecules through thioimine and application thereof | 清华大学 | 2026-05-19 | — | — | CN | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1999001427-A2 | NOVEL NITRIC OXIDE-RELEASING AMIDINE- AND ENAMINE-DERIVED DIAZENIUMDIOLATES, COMPOSITIONS AND USES THEREOF AND METHOD OF MAKING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 1999-01-14 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| US-4963588-A | BLOOD DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-10-16 | — | — | US | claimed |
| EP-0384302-A2 | Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome | Nippon Kayaku Kabushiki Kaisha (JP) | 1990-08-29 | — | — | EP | claimed |
| US-4281180-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-07-28 | — | — | US | claimed |
| US-4052449-A | BIOLOGICALLY ACTIVE SUBSTANCE, BESTATIN, AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-10-04 | — | — | US | claimed |
| US-4029547-A | Biologically active substance, bestatin, and production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-06-14 | — | — | US | claimed |